You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePomalidomide
Accession NumberDB08910
TypeSmall Molecule
GroupsApproved
DescriptionPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • CC-4047
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImnovidCapsule, hard4 mgOral useCelgene Europe Ltd2013-08-05Not applicableEu
ImnovidCapsule, hard1 mgOral useCelgene Europe Ltd2013-08-05Not applicableEu
ImnovidCapsule, hard2 mgOral useCelgene Europe Ltd2013-08-05Not applicableEu
ImnovidCapsule, hard3 mgOral useCelgene Europe Ltd2013-08-05Not applicableEu
Pomalystcapsule4 mgoralCelgene Inc2014-02-24Not applicableCanada
Pomalystcapsule1 mg/1oralCelgene Corporation2013-02-18Not applicableUs
Pomalystcapsule1 mgoralCelgene Inc2014-02-24Not applicableCanada
Pomalystcapsule2 mg/1oralCelgene Corporation2013-02-18Not applicableUs
Pomalystcapsule2 mgoralCelgene Inc2014-02-24Not applicableCanada
Pomalystcapsule3 mg/1oralCelgene Corporation2013-02-18Not applicableUs
Pomalystcapsule3 mgoralCelgene Inc2014-02-24Not applicableCanada
Pomalystcapsule4 mg/1oralCelgene Corporation2013-02-18Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ImnovidNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIID2UX06XLB5
CAS number19171-19-8
WeightAverage: 273.2441
Monoisotopic: 273.074955855
Chemical FormulaC13H11N3O4
InChI KeyInChIKey=UVSMNLNDYGZFPF-UHFFFAOYNA-N
InChI
InChI=1/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
IUPAC Name
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
SMILES
NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O
Taxonomy
ClassificationNot classified
Pharmacology
IndicationPomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
PharmacodynamicsPomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times).
Mechanism of actionPromalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.
Related Articles
AbsorptionPomalidomide is generally well absorbed. The major circulating component is the parent compound. Tmax, single oral dose = 2 -3 hours. When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows: AUC(T) = 400 ng.hr/mL; Cmax = 75 ng/mL. Promalidomide accumulates following multiple doses.
Volume of distribution

Mean apparent volume of distribution (Vd/F), steady-state = 62 – 138 L

Protein binding12-44% protein bound. It is not concentration dependent.
Metabolism

Promalidomide is hepatically metabolized by CYP1A2 and CYP3A4. The metabolites are 26-fold less active than the parent compound. Minor contributions from CYP2C19 and CYP2D6 have been observed in vitro.

Route of eliminationWhen a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.
Half lifeHealthy subjects = 9.4 hours; Multiple myeloma patients = 7.5 hours.
Clearance

Total body clearance = 7-10 L/hour

ToxicityMost common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9653
Blood Brain Barrier+0.8304
Caco-2 permeable-0.6419
P-glycoprotein substrateSubstrate0.5264
P-glycoprotein inhibitor INon-inhibitor0.5983
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.847
CYP450 2C9 substrateNon-substrate0.844
CYP450 2D6 substrateNon-substrate0.8882
CYP450 3A4 substrateSubstrate0.5079
CYP450 1A2 substrateNon-inhibitor0.8863
CYP450 2C9 inhibitorNon-inhibitor0.8428
CYP450 2D6 inhibitorNon-inhibitor0.9002
CYP450 2C19 inhibitorNon-inhibitor0.8513
CYP450 3A4 inhibitorNon-inhibitor0.7289
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8686
Ames testNon AMES toxic0.7979
CarcinogenicityNon-carcinogens0.9081
BiodegradationNot ready biodegradable0.9858
Rat acute toxicity2.5862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9885
hERG inhibition (predictor II)Non-inhibitor0.7765
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsule, hardOral use1 mg
Capsule, hardOral use2 mg
Capsule, hardOral use3 mg
Capsule, hardOral use4 mg
Capsuleoral1 mg/1
Capsuleoral1 mg
Capsuleoral2 mg
Capsuleoral2 mg/1
Capsuleoral3 mg
Capsuleoral3 mg/1
Capsuleoral4 mg
Capsuleoral4 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5635517 No1996-07-242016-07-24Us
US6045501 No1998-08-282018-08-28Us
US6315720 No2000-10-232020-10-23Us
US6316471 No1996-08-102016-08-10Us
US6476052 No1996-07-242016-07-24Us
US6561976 No1998-08-282018-08-28Us
US6561977 No2000-10-232020-10-23Us
US6755784 No2000-10-232020-10-23Us
US6908432 No1998-08-282018-08-28Us
US8158653 No1996-08-102016-08-10Us
US8198262 No2004-10-192024-10-19Us
US8204763 No1998-08-282018-08-28Us
US8315886 No2000-10-232020-10-23Us
US8589188 No1998-08-282018-08-28Us
US8626531 No2000-10-232020-10-23Us
US8673939 No2003-05-152023-05-15Us
US8735428 No2003-05-152023-05-15Us
US8828427 No2011-06-212031-06-21Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility2.57 mg/mLALOGPS
logP0.02ALOGPS
logP-0.16ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.59ChemAxon
pKa (Strongest Basic)1.56ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity69.03 m3·mol-1ChemAxon
Polarizability25.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017 ]
  2. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498 ]
  3. Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA: Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498. Print 2013. [PubMed:23690693 ]
External Links
ATC CodesL04AX06
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (292 KB)
MSDSDownload (479 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pomalidomide.
AbirateroneThe serum concentration of Pomalidomide can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pomalidomide.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pomalidomide.
AcetaminophenThe serum concentration of Pomalidomide can be increased when it is combined with Acetaminophen.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pomalidomide.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Pomalidomide.
AfatinibThe serum concentration of Pomalidomide can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pomalidomide.
AlbendazoleThe serum concentration of Pomalidomide can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Pomalidomide can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Pomalidomide can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pomalidomide.
AlfentanilThe serum concentration of Pomalidomide can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pomalidomide.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pomalidomide.
AmantadineThe serum concentration of Pomalidomide can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Pomalidomide can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Pomalidomide can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Pomalidomide.
AmitriptylineThe serum concentration of Pomalidomide can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Amitriptyline.
AmlodipineThe serum concentration of Pomalidomide can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pomalidomide.
AmoxapineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pomalidomide.
AmprenavirThe serum concentration of Pomalidomide can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Pomalidomide can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pomalidomide.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pomalidomide.
AstemizoleThe serum concentration of Pomalidomide can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Pomalidomide can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Pomalidomide can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Pomalidomide can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Pomalidomide can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Pomalidomide.
AzelastinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Pomalidomide can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Pomalidomide can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pomalidomide.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pomalidomide.
BenzocaineThe serum concentration of Pomalidomide can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pomalidomide.
BepridilThe serum concentration of Pomalidomide can be increased when it is combined with Bepridil.
BevacizumabBevacizumab may increase the cardiotoxic activities of Pomalidomide.
BexaroteneThe serum concentration of Pomalidomide can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Pomalidomide can be increased when it is combined with Biperiden.
BoceprevirThe metabolism of Pomalidomide can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Pomalidomide can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Pomalidomide can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Pomalidomide can be increased when it is combined with Bosutinib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
BrimonidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.
BromocriptineThe serum concentration of Pomalidomide can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pomalidomide.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pomalidomide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pomalidomide.
BuprenorphineThe serum concentration of Pomalidomide can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Buprenorphine.
BuspironeThe serum concentration of Pomalidomide can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pomalidomide.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Pomalidomide.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pomalidomide.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Pomalidomide.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pomalidomide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.
CabazitaxelThe serum concentration of Pomalidomide can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Pomalidomide can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Pomalidomide can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Pomalidomide can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Pomalidomide can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pomalidomide.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pomalidomide.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.
CarvedilolThe serum concentration of Pomalidomide can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Pomalidomide can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Pomalidomide can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pomalidomide.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pomalidomide.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pomalidomide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pomalidomide.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pomalidomide.
ChloroquineThe serum concentration of Pomalidomide can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide.
ChlorpromazineThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Pomalidomide can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pomalidomide.
CholesterolThe serum concentration of Pomalidomide can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Pomalidomide can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Pomalidomide can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Pomalidomide can be decreased when it is combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pomalidomide.
CiprofloxacinThe serum concentration of Pomalidomide can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Citalopram.
CitalopramThe serum concentration of Pomalidomide can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Pomalidomide can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Pomalidomide can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pomalidomide.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Pomalidomide.
ClofazimineThe serum concentration of Pomalidomide can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pomalidomide.
ClomipramineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clomipramine.
ClomipramineThe serum concentration of Pomalidomide can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pomalidomide.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pomalidomide.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pomalidomide.
ClotrimazoleThe metabolism of Pomalidomide can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clozapine.
CobicistatThe serum concentration of Pomalidomide can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pomalidomide.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pomalidomide.
ColchicineThe serum concentration of Pomalidomide can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Pomalidomide can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Pomalidomide can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Pomalidomide can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pomalidomide.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pomalidomide.
CyclosporineThe metabolism of Pomalidomide can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pomalidomide.
Cyproterone acetateThe serum concentration of Pomalidomide can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Pomalidomide can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Pomalidomide can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pomalidomide.
DapoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapoxetine.
DarunavirThe metabolism of Pomalidomide can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Pomalidomide can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Pomalidomide can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Pomalidomide can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Pomalidomide.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.
DesipramineThe serum concentration of Pomalidomide can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pomalidomide.
DesloratadineThe serum concentration of Pomalidomide can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Pomalidomide.
DexamethasoneThe serum concentration of Pomalidomide can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pomalidomide.
DextromethorphanThe serum concentration of Pomalidomide can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pomalidomide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pomalidomide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pomalidomide.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pomalidomide.
DiclofenacThe serum concentration of Pomalidomide can be increased when it is combined with Diclofenac.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pomalidomide.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pomalidomide.
DigoxinDigoxin may decrease the cardiotoxic activities of Pomalidomide.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.
DihydroergotamineThe metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pomalidomide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pomalidomide.
DiltiazemThe metabolism of Pomalidomide can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pomalidomide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pomalidomide.
DipyridamoleThe serum concentration of Pomalidomide can be increased when it is combined with Dipyridamole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Pomalidomide.
DoxazosinThe serum concentration of Pomalidomide can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Pomalidomide can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Doxepin.
DoxorubicinThe serum concentration of Pomalidomide can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Pomalidomide can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
DoxylamineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pomalidomide.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
DronedaroneThe metabolism of Pomalidomide can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Pomalidomide.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pomalidomide.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pomalidomide.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pomalidomide.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Pomalidomide.
EfavirenzThe serum concentration of Pomalidomide can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Efavirenz.
ElbasvirThe serum concentration of Pomalidomide can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Pomalidomide can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pomalidomide.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pomalidomide.
EnzalutamideThe serum concentration of Pomalidomide can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Pomalidomide can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Pomalidomide can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Pomalidomide can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Pomalidomide can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pomalidomide.
EstramustineThe serum concentration of Pomalidomide can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Pomalidomide can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Pomalidomide can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pomalidomide.
EthanolPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pomalidomide.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pomalidomide.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pomalidomide.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pomalidomide.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pomalidomide.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Pomalidomide.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pomalidomide.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pomalidomide.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pomalidomide.
EtoperidoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etoperidone.
EtoposideThe serum concentration of Pomalidomide can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pomalidomide.
EtravirineThe serum concentration of Pomalidomide can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Pomalidomide.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pomalidomide.
FelodipineThe serum concentration of Pomalidomide can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pomalidomide.
FenfluramineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fenfluramine.
FentanylThe serum concentration of Pomalidomide can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fentanyl.
FexofenadineThe serum concentration of Pomalidomide can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fexofenadine.
FidaxomicinThe serum concentration of Pomalidomide can be increased when it is combined with Fidaxomicin.
FingolimodPomalidomide may increase the immunosuppressive activities of Fingolimod.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pomalidomide.
FluconazoleThe metabolism of Pomalidomide can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pomalidomide.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pomalidomide.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pomalidomide.
FluoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluoxetine.
FluoxetineThe serum concentration of Pomalidomide can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Pomalidomide can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Flupentixol.
FluphenazineThe serum concentration of Pomalidomide can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluphenazine.
FlurazepamThe serum concentration of Pomalidomide can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pomalidomide.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Pomalidomide.
FluvoxamineThe serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluvoxamine.
FosamprenavirThe metabolism of Pomalidomide can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Pomalidomide.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pomalidomide.
Fusidic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Pomalidomide.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pomalidomide.
GefitinibThe serum concentration of Pomalidomide can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Pomalidomide can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pomalidomide.
GlyburideThe serum concentration of Pomalidomide can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Pomalidomide can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Pomalidomide can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Pomalidomide can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pomalidomide.
HaloperidolThe serum concentration of Pomalidomide can be increased when it is combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pomalidomide.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pomalidomide.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pomalidomide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pomalidomide.
HydrocortisoneThe serum concentration of Pomalidomide can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
HydroxyzineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Hydroxyzine.
IdelalisibThe serum concentration of Pomalidomide can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.
ImatinibThe metabolism of Pomalidomide can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Pomalidomide can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Indalpine.
IndinavirThe serum concentration of Pomalidomide can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Pomalidomide can be increased when it is combined with Indomethacin.
IsavuconazoniumThe metabolism of Pomalidomide can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pomalidomide.
IsradipineThe metabolism of Pomalidomide can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Pomalidomide can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Pomalidomide can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Pomalidomide can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pomalidomide.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pomalidomide.
KetoconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pomalidomide.
LansoprazoleThe serum concentration of Pomalidomide can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Pomalidomide can be increased when it is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pomalidomide.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Pomalidomide.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pomalidomide.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pomalidomide.
LevofloxacinThe serum concentration of Pomalidomide can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pomalidomide.
LevomilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pomalidomide.
LevothyroxineThe serum concentration of Pomalidomide can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Pomalidomide can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Lidocaine.
LiothyronineThe serum concentration of Pomalidomide can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Pomalidomide can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Pomalidomide can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Pomalidomide.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pomalidomide.
LomitapideThe serum concentration of Pomalidomide can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Pomalidomide can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Pomalidomide can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Pomalidomide can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pomalidomide.
LosartanThe serum concentration of Pomalidomide can be increased when it is combined with Losartan.
LovastatinThe metabolism of Pomalidomide can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pomalidomide.
Lu AA21004The risk or severity of adverse effects can be increased when Pomalidomide is combined with Lu AA21004.
LuliconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Pomalidomide can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Magnesium Sulfate.
MaprotilineThe serum concentration of Pomalidomide can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Maprotiline.
MebendazoleThe serum concentration of Pomalidomide can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pomalidomide.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Pomalidomide.
MefloquineThe serum concentration of Pomalidomide can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Pomalidomide can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pomalidomide.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Pomalidomide.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pomalidomide.
MeprobamateThe serum concentration of Pomalidomide can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pomalidomide.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pomalidomide.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.
MethadoneThe serum concentration of Pomalidomide can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pomalidomide.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pomalidomide.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pomalidomide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pomalidomide.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Pomalidomide.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pomalidomide.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pomalidomide.
MetoprololThe serum concentration of Pomalidomide can be increased when it is combined with Metoprolol.
MetyrosinePomalidomide may increase the sedative activities of Metyrosine.
MexiletineThe serum concentration of Pomalidomide can be increased when it is combined with Mexiletine.
MibefradilThe serum concentration of Pomalidomide can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Pomalidomide can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Midazolam.
MifepristoneThe metabolism of Pomalidomide can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
MirtazapinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pomalidomide.
MitomycinThe serum concentration of Pomalidomide can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Pomalidomide can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Pomalidomide can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Pomalidomide can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pomalidomide.
MorphineThe serum concentration of Pomalidomide can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.
NabiloneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Nabilone.
NafcillinThe serum concentration of Pomalidomide can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pomalidomide.
NaltrexoneThe serum concentration of Pomalidomide can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Pomalidomide can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.
NefazodoneThe serum concentration of Pomalidomide can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Pomalidomide can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Pomalidomide can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Pomalidomide can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Pomalidomide can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Pomalidomide can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Pomalidomide can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Pomalidomide can be decreased when combined with Nilotinib.
NisoldipineThe serum concentration of Pomalidomide can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Pomalidomide can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Nitrazepam.
NitrendipineThe serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pomalidomide.
NorethisteroneThe serum concentration of Pomalidomide can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Pomalidomide.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pomalidomide.
OlanzapineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Olanzapine.
OlaparibThe metabolism of Pomalidomide can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pomalidomide.
OmeprazoleThe serum concentration of Pomalidomide can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pomalidomide.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Pomalidomide.
OrphenadrinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pomalidomide.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Pomalidomide.
OsimertinibThe serum concentration of Pomalidomide can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Pomalidomide.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pomalidomide.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pomalidomide.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pomalidomide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pomalidomide.
P-NitrophenolThe serum concentration of Pomalidomide can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Pomalidomide can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pomalidomide.
Palmitic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Pomalidomide can be increased when it is combined with Pantoprazole.
ParaldehydePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Pomalidomide.
ParoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.
ParoxetineThe serum concentration of Pomalidomide can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pomalidomide.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Pomalidomide.
PerindoprilThe serum concentration of Pomalidomide can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Pomalidomide.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pomalidomide.
PhenobarbitalThe serum concentration of Pomalidomide can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Pomalidomide.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pomalidomide.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.
PimozideThe serum concentration of Pomalidomide can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pomalidomide.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pomalidomide.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Pomalidomide.
Platelet Activating FactorThe serum concentration of Pomalidomide can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Pomalidomide can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Posaconazole.
PramipexolePomalidomide may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Pomalidomide.
PravastatinThe serum concentration of Pomalidomide can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pomalidomide.
PrazosinThe serum concentration of Pomalidomide can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Pomalidomide can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Pomalidomide.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pomalidomide.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Pomalidomide.
ProbenecidThe serum concentration of Pomalidomide can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pomalidomide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.
ProgesteroneThe serum concentration of Pomalidomide can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.
PromethazineThe serum concentration of Pomalidomide can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Promethazine.
PropafenoneThe serum concentration of Pomalidomide can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pomalidomide.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pomalidomide.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Pomalidomide.
PropranololThe serum concentration of Pomalidomide can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Pomalidomide can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Pomalidomide.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pomalidomide.
QuercetinThe serum concentration of Pomalidomide can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.
QuinacrineThe serum concentration of Pomalidomide can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Pomalidomide can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Pomalidomide can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rabies vaccine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide.
RanitidineThe serum concentration of Pomalidomide can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Pomalidomide can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Pomalidomide can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Pomalidomide can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pomalidomide.
ReserpineThe serum concentration of Pomalidomide can be decreased when it is combined with Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Reserpine.
RifabutinThe metabolism of Pomalidomide can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Pomalidomide can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Pomalidomide can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Pomalidomide can be increased when it is combined with Rilpivirine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.
RitonavirThe serum concentration of Pomalidomide can be decreased when it is combined with Ritonavir.
RoflumilastRoflumilast may increase the immunosuppressive activities of Pomalidomide.
RolapitantThe serum concentration of Pomalidomide can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Pomalidomide.
RopinirolePomalidomide may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Pomalidomide can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pomalidomide.
RotigotinePomalidomide may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pomalidomide.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Pomalidomide.
SaquinavirThe serum concentration of Pomalidomide can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Pomalidomide can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pomalidomide.
SelegilineThe serum concentration of Pomalidomide can be increased when it is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Pomalidomide.
SertralineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sertraline.
SertralineThe serum concentration of Pomalidomide can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pomalidomide.
SildenafilThe metabolism of Pomalidomide can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Pomalidomide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Pomalidomide can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Pomalidomide can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.
SirolimusThe serum concentration of Pomalidomide can be decreased when it is combined with Sirolimus.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Pomalidomide.
SorafenibThe serum concentration of Pomalidomide can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Pomalidomide can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Pomalidomide can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Pomalidomide can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Stiripentol.
StreptozocinThe serum concentration of Pomalidomide can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.
SulfinpyrazoneThe serum concentration of Pomalidomide can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Pomalidomide can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Pomalidomide.
SumatriptanThe serum concentration of Pomalidomide can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Pomalidomide can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Suvorexant.
TacrineThe serum concentration of Pomalidomide can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pomalidomide.
TamoxifenThe serum concentration of Pomalidomide can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pomalidomide.
TasimelteonThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Pomalidomide can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Pomalidomide can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Pomalidomide can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pomalidomide.
TemsirolimusThe serum concentration of Pomalidomide can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Pomalidomide can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Pomalidomide can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Pomalidomide can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Pomalidomide can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Pomalidomide can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pomalidomide.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pomalidomide.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pomalidomide.
ThalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Pomalidomide.
TheophyllineThe metabolism of Pomalidomide can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pomalidomide.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pomalidomide.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pomalidomide.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pomalidomide.
TicagrelorThe serum concentration of Pomalidomide can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Pomalidomide can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Pomalidomide.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.
TocilizumabThe serum concentration of Pomalidomide can be decreased when it is combined with Tocilizumab.
TofacitinibPomalidomide may increase the immunosuppressive activities of Tofacitinib.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.
TolvaptanThe serum concentration of Pomalidomide can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pomalidomide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pomalidomide.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Pomalidomide.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pomalidomide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Pomalidomide.
TrazodoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trazodone.
TrazodoneThe serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pomalidomide.
TrifluoperazineThe serum concentration of Pomalidomide can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Pomalidomide can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Triflupromazine.
TrimethoprimThe serum concentration of Pomalidomide can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Pomalidomide can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pomalidomide.
TroleandomycinThe serum concentration of Pomalidomide can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pomalidomide.
VemurafenibThe serum concentration of Pomalidomide can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Pomalidomide can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Pomalidomide can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pomalidomide.
VilazodoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Vilazodone.
VinblastineThe serum concentration of Pomalidomide can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Pomalidomide can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Pomalidomide can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Pomalidomide can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Pomalidomide.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pomalidomide.
ZimelidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Zimelidine.
ZimelidineThe serum concentration of Pomalidomide can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Pomalidomide can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Pomalidomide.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Pomalidomide.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pomalidomide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pomalidomide.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Pomalidomide.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pomalidomide.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly an...
Gene Name:
CRBN
Uniprot ID:
Q96SW2
Molecular Weight:
50545.375 Da
References
  1. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498 ]
  2. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity. Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/science.1177319. [PubMed:20223979 ]
  3. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. [PubMed:22552008 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tumor necrosis factor receptor binding
Specific Function:
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs ...
Gene Name:
TNF
Uniprot ID:
P01375
Molecular Weight:
25644.15 Da
References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Ferguson GD, Jensen-Pergakes K, Wilkey C, Jhaveri U, Richard N, Verhelle D, De Parseval LM, Corral LG, Xie W, Morris CL, Brady H, Chan K: Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007 Mar;27(2):210-20. Epub 2007 Feb 17. [PubMed:17308870 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on June 20, 2013 16:45 / Updated on September 24, 2016 02:17